Objective To retrospectively analyze the adverse effects and efficacy of apatinib monotherapy,combination chemotherapy,or immune second-line treatment for advanced gastric cancer,and to explore the factors that influence treatment efficacy.Methods The study involved 145 patients with advanced gastric cancer who were admitted to the First Affiliated Hospital of Bengbu Medical University between January 2015 and December 2020.The patients were divid-ed into three groups based on their medication regimen:apatinib single-agent group(n=36),combination chemotherapy group(n=94)and combination immunization group(n=15).The effectiveness of the three second-line treatments for advanced gastric cancer was compared using the Kaplan-Meier method.The study employed a Cox regression model to an-alyze the factors that impact treatment efficacy.The study employed a Cox regression model to analyze the factors that im-pact treatment efficacy.Results In the second-line treatment of advanced gastric cancer.The combination chemotherapy and combined immunization group showed significantly higher median progression-free survival(mPFS)and median over-all survival(mOS)compared to the apatinib monotherapy group(mPFS,8.3 months vs.3.6 months,P＜0.001;8.4 months vs.3.6 months,P=0.003;mOS,11.0 months vs.7.5 months,P＜0.001;14.0 months vs.7.5 months,P＜0.001).The objective response rates(ORRs)for the three treatments were 5.56％,18.09％and 26.67％(P=0.097),respectively.The disease control rates(DCRs)were 19.44％,37.23％and 33.33％(P=0.151),respec-tively.However,the differences were not statistically significant(P＞0.05).The incidence of grade Ⅲ-Ⅳ adverse reac-tions among the three treatment options was 22.2％(8/36),19.1％(18/94)and 26.7％(4/15),respectively,and the difference was not statistically significant(P=0.863).The statistical analysis revealed that there was a significant correlation between the ECOG score,peritoneal metastasis,and combination and progression-free survival in patients(P＜0.001).Conclusion In the second-line treatment of advanced gastric cancer,combining apatinib with chemotherapy or immunotherapy can lead to better efficacy while maintaining reliable safety.
维普
万方数据